Artelo Biosciences (ARTL)
(Real Time Quote from BATS)
$1.10 USD
0.00 (0.00%)
Updated Sep 19, 2024 10:54 AM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ARTL 1.10 0.00(0.00%)
Will ARTL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ARTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARTL
Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study
ARTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ARTL
Optimistic Buy Rating for Artelo Biosciences Amidst Growing Focus on Cancer Cachexia Therapies
UK dividends calendar
UK dividends calendar
UK dividends calendar
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference